WA-SPIE
30.9.2021 11:05:11 CEST | Business Wire | Press release
SPIE, the international society for optics and photonics , and the University of Birmingham have announced the establishment of the SPIE Optics and Photonics Champion Academy fund. The new endowment was announced this morning, during SPIE Photonex + Vacuum Technologies in Glasgow, Scotland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210930005066/en/
The $400,000 gift from the SPIE Endowment Matching Program will be matched 100% by the university, and the $800,000 fund will create and support the SPIE Optics and Photonics Champion Academy. The cohort-focused program will engage in areas of public interest in the fields of quantum technology and biomedical imaging and data sciences: one of the first projects will address pandemics. The program will be led by Professor and Principal Investigator of the UK Quantum Technology Hub Sensors and Timing Kai Bongs , and Professor of Computational Life Sciences Iain Styles .
The SPIE Optics and Photonics Champion Academy will support University of Birmingham students in a variety of ways which include expanding cross-disciplinary educational opportunities in optics and photonics; offering students hands-on support and training to become influential science communicators and advocates of optics and photonics; and by utilizing a range of stipends, awards, and activity grants, which will be supplemented with professional development and mentoring opportunities from the university’s academic leaders as well as from external experts.
The program will focus particularly on students in underrepresented groups, early-career researchers, and PhD students in order to establish and build a broad, diverse, and inclusive network of science advocates, especially in the area of optics and photonics.
“We are delighted to be able to work with SPIE to launch this unique Academy at the University of Birmingham,” said Professor Bongs. “This initiative will help to accelerate the growth of optics and photonics expertise, which will have great impact far beyond the university. Our hope is to not only encourage this learning, but to also create awareness of the huge importance of this subject area in tackling real-world problems.”
“By equipping early-career optics and photonics researchers and PhD students with skills in advanced data analysis, we will help to accelerate the translation of these exciting technologies from the laboratory to their adoption in real-world applications,” added Professor Styles. “Our SPIE Champions will be able to work with experts in diverse application areas such as healthcare and climate monitoring to develop end-to-end optics-based solutions with integrated analytics for some of our most pressing challenges.”
“By offering direct, experiential training in quantum technology and biomedical imaging as well as highlighting various career options in the field, the SPIE Optics and Photonics Champion Academy will develop a natural pipeline of future professional scientists and engineers in these fields,” noted SPIE President David Andrews . “And by encouraging students to actively raise awareness of the impact of optics and photonics to their contemporaries, peers, and younger colleagues, the program will be creating visible, engaged role models for future generations.”
The SPIE Endowment Matching Program was established in 2019 to increase international capacity in the teaching and research of optics and photonics, and to date has given more than $3.4 million in matching gifts, resulting in more than $9 million in dedicated funds. The SPIE Endowment Matching Program supports optics and photonics education and the future of the industry by contributing a match of up to $500,000 per award to college and university programs with optics and photonics degrees, or with other disciplines allied to the SPIE mission.
About SPIE
SPIE is the international society for optics and photonics, an educational not-for-profit organization founded in 1955 to advance light-based science, engineering, and technology. The Society serves more than 258,000 constituents from 184 countries, offering conferences and their published proceedings, continuing education, books, journals, and the SPIE Digital Library. In 2020, SPIE provided over $5 million in community support including scholarships and awards, outreach and advocacy programs, travel grants, public policy, and educational resources. www.spie.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005066/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
